The authors postulated that the combination of radiotherapy and CD40 agonism was able to disrupt and re-organise the links between the innate and adaptive immune systems in a non-redundant way, hence resulting in tumours that were re-sensitised to anti-PD-1 and anti-CTLA-4 therapy. This evidence concerns the gene CTLA4 and neoplasm.